[Mildronate in combined treatment of chronic cardiac insufficiency].
Nedoshivin
A O
AO
Kutuzova
A E
AE
Perepech
N B
NB
D002302:Cardiac Output / Q000187:drug effects; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004452:Echocardiography; D017079:Exercise Tolerance / Q000187:drug effects; D005500:Follow-Up Studies; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000627:therapeutic use*; D008875:Middle Aged; D012449:Safety; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
D002317:Cardiovascular Agents; D004232:Diuretics; D008763:Methylhydrazines; D014665:Vasodilator Agents; C050147:3-(2,2,2-trimethylhydrazine)propionate